Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment

Authors

D. Pouessel, Y. Neuzillet, L.S. Mertens, M.S. van der Heijden, J. de Jong, J. Sanders, D. Peters, K. Leroy, A. Manceau, P. Maille, P. Soyeux, A. Moktefi, F. Semprez, D. Vordos, A. de la Taille, C.D. Hurst, D.C. Tomlinson, P. Harnden, P.J. Bostrom, T. Mirtti, S. Horenblas, Y. Loriot, N. Houédé, C. Chevreau, P. Beuzeboc, S.F. Shariat, A.I. Sagalowsky, R. Ashfaq, M. Burger, M.A.S. Jewett, A.R. Zlotta, A. Broeks, B. Bapat, M.A. Knowles, Y. Lotan, T.H. van der Kwast, S. Culine, Y. Allory, B.W.G. van Rhijn